Litigation Details for Keryx Biopharmaceuticals, Inc. v. Lupin Ltd. (D. Del. 2018)
✉ Email this page to a colleague
Keryx Biopharmaceuticals, Inc. v. Lupin Ltd. (D. Del. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-12-12 |
| Court | District Court, D. Delaware | Date Terminated | 2020-10-05 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Parties | KERYX BIOPHARMACEUTICALS, INC. | ||
| Patents | 7,767,851; 8,093,423; 8,299,298; 8,338,642; 8,609,896; 8,754,257; 8,754,258; 8,846,976; 8,901,349; 9,050,316; 9,328,133; 9,387,191; 9,757,416 | ||
| Attorneys | David A. Bilson | ||
| Firms | Phillips, McLaughlin & Hall, P.A. | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Keryx Biopharmaceuticals, Inc. v. Lupin Ltd.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Keryx Biopharmaceuticals, Inc. v. Lupin Ltd. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-12-12 | 1 | United States Patent Nos. 5,753,706 (the “’706 patent”); 7,767,851 (the “’851 patent”); 8,093,423 (the…(the “’423 patent”); 8,299,298 (the “’298 patent”); 8,338,642 (the “’642 patent”); 8,609,896 (the “’896…’896 patent”); 8,754,257 (the “’257 patent”); 8,754,258 (the “’258 patent”); 8,846,976 (the “’976 patent…,349 (the “’349 patent”); 9,050,316 (the “’316 patent”); 9,328,133 (the “’133 patent”); 9,757,416 (the… #: 2 “’416 patent”); and 9,387,191 (the “’191 patent”) (collectively, the “patents-in-suit”), owned | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
